Show simple item record

dc.contributor.authorLanghe, Ream
dc.contributor.authorNorris, Lucy
dc.contributor.authorSaadeh, Feras Abu
dc.contributor.authorBlackshields, Gordon
dc.contributor.authorVarley, Rachel
dc.contributor.authorHarrison, Ashling
dc.contributor.authorGleeson, Noreen
dc.contributor.authorSpillane, Cathy
dc.contributor.authorMartin, Cara
dc.contributor.authorO'Donnell, Dearbhaile M
dc.contributor.authorD'Arcy, Tom
dc.contributor.authorO'Leary, John
dc.contributor.authorO'Toole, Sharon
dc.date.accessioned2015-08-05T15:00:50Zen
dc.date.available2015-08-05T15:00:50Zen
dc.date.issued2015-01-28en
dc.identifier.citationA novel serum microRNA panel to discriminate benign from malignant ovarian disease. 2015, 356 (2 Pt B):628-36 Cancer Lett.en
dc.identifier.issn1872-7980en
dc.identifier.pmid25451316en
dc.identifier.doi10.1016/j.canlet.2014.10.010en
dc.identifier.urihttp://hdl.handle.net/10147/565660en
dc.description.abstractOvarian cancer is the seventh most common cancer in women and the most frequent cause of gynaecological malignancy-related mortality in women. Currently, no standardized reliable screening test exists. MicroRNA profiling has allowed the identification of signatures associated with diagnosis, prognosis and response to treatment of human tumours. The aim of this study was to determine if a microRNA signature could distinguish between malignant and benign ovarian disease. A training set of 5 serous ovarian carcinomas and 5 benign serous cystadenomas were selected for the initial experiments. The validation set included 20 serous ovarian carcinomas and 20 benign serous cystadenomas. The serum/plasma focus microRNA Exiqon panel was used for the training set. For the validation set a pick and mix Exiqon panel, which focuses on microRNAs of interest was used. A panel of 4 microRNAs (let-7i-5p, miR-122, miR-152-5p and miR-25-3p) was significantly down regulated in cancer patients. These microRNAs target WNT signalling, AKT/mTOR and TLR-4/MyD88, which have previously been found to play a role in ovarian carcinogenesis and chemoresistance. let-7i-5p, miR-122, miR-152-5p and miR-25-3p could act as diagnostic biomarkers in ovarian cancer.
dc.language.isoenen
dc.rightsArchived with thanks to Cancer lettersen
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAged, 80 and overen
dc.subject.meshCase-Control Studiesen
dc.subject.meshCystadenocarcinoma, Serousen
dc.subject.meshFemaleen
dc.subject.meshFollow-Up Studiesen
dc.subject.meshGene Expression Profilingen
dc.subject.meshGene Expression Regulation, Neoplasticen
dc.subject.meshHemolysisen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMicroRNAsen
dc.subject.meshMiddle Ageden
dc.subject.meshNeoplasm Stagingen
dc.subject.meshOvarian Neoplasmsen
dc.subject.meshPrognosisen
dc.subject.meshRNA, Messengeren
dc.subject.meshReal-Time Polymerase Chain Reactionen
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen
dc.subject.meshTumor Markers, Biologicalen
dc.titleA novel serum microRNA panel to discriminate benign from malignant ovarian disease.en
dc.typeArticleen
dc.identifier.journalCancer lettersen
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
refterms.dateFOA2018-08-27T03:09:45Z
html.description.abstractOvarian cancer is the seventh most common cancer in women and the most frequent cause of gynaecological malignancy-related mortality in women. Currently, no standardized reliable screening test exists. MicroRNA profiling has allowed the identification of signatures associated with diagnosis, prognosis and response to treatment of human tumours. The aim of this study was to determine if a microRNA signature could distinguish between malignant and benign ovarian disease. A training set of 5 serous ovarian carcinomas and 5 benign serous cystadenomas were selected for the initial experiments. The validation set included 20 serous ovarian carcinomas and 20 benign serous cystadenomas. The serum/plasma focus microRNA Exiqon panel was used for the training set. For the validation set a pick and mix Exiqon panel, which focuses on microRNAs of interest was used. A panel of 4 microRNAs (let-7i-5p, miR-122, miR-152-5p and miR-25-3p) was significantly down regulated in cancer patients. These microRNAs target WNT signalling, AKT/mTOR and TLR-4/MyD88, which have previously been found to play a role in ovarian carcinogenesis and chemoresistance. let-7i-5p, miR-122, miR-152-5p and miR-25-3p could act as diagnostic biomarkers in ovarian cancer.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
NovelSerumMicroRNAPanel.pdf
Size:
148.5Kb
Format:
PDF
Description:
Author Final Manuscript

This item appears in the following Collection(s)

Show simple item record